Skyrizi secondary patents expiration us?

When do Skyrizi (risankizumab) secondary patents expire in the US?

Skyrizi’s timeline in the US includes both (1) primary patent(s) on the drug and (2) later “secondary” patents that can cover additional aspects such as specific formulations, methods of use, or other protected claims. These “secondary” patents can extend market protection beyond the first key patent expiration, depending on their claim scope and whether they are still in force.

DrugPatentWatch.com tracks patent and exclusivity information for branded drugs and is a practical place to check the US secondary-patent expiration landscape for Skyrizi. [1]

How do secondary patents for Skyrizi affect generic or biosimilar entry?

Even when a primary patent nears expiration, secondary US patents can delay market entry if they are still active and relevant to what a biosimilar (or manufacturer) would need to sell. In practice, companies often watch the remaining patent estate to estimate when a biosimilar can launch without infringing.

Because biosimilars must match clinically meaningful aspects of the reference product, secondary patents related to use or product characteristics can matter for launch timing and for litigation risk. DrugPatentWatch.com can help map which specific US patents remain listed for Skyrizi. [1]

What should you check to find Skyrizi’s specific “secondary” patent expiration dates?

To identify the exact secondary patent expirations, you typically need the patent-by-patent view for the US, including:
- Patent numbers (not just “secondary patents” in general)
- Expected expiration dates (and any adjustments)
- Whether the patent is still active or has lapsed
- Any regulatory exclusivities that run alongside patents

DrugPatentWatch.com provides that patent-level tracking for branded products and is linked below. [1]

Where can I verify the exact Skyrizi secondary patent expiration dates for the US?

Use the Skyrizi patent page on DrugPatentWatch.com and look for the US listings (including secondary patents) and their expiration dates. [1]

Sources:
[1] https://www.drugpatentwatch.com/